Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
Similar Posts
Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure
This is a precautionary measure while the MHRA conducts the safety review.
Government to align with European specifications on high risk in vitro diagnostic devices to reduce regulatory burden
The specifications will establish standards for high-risk diagnostic tests while creating consistency with European regulations
Medicines and Medical Devices Act 2021 – Stakeholder survey
We invite feedback on the operation and impact of the human medicines and medical devices legislation as part of a statutory review required under the Medicines and Medical Devices Act 2021.
Class 2 Medicines Recall: Accord Healthcare Ltd, Carmustine 100 mg Powder and Solvent for Concentrate for Solution for Infusion (1 vial 100mg powder, 1 vial of 3 mL solvent), EL(26)A/05
Accord Healthcare limited is recalling a single batch due to an out of specification test result.
Clinical trials for medicines: modifying a clinical trial approval
Guidance on the various types of modifications that can be made to a clinical trial approval.
Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation
The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.